Home / Health / FDA Approves New Lantheus Prostate Cancer Scan
FDA Approves New Lantheus Prostate Cancer Scan
7 Mar
Summary
- FDA approved a new Lantheus prostate cancer imaging agent formulation.
- The new Pylarify version increases production capacity by 50%.
- This aims to improve patient access to vital cancer scans.
On March 6, 2026, the U.S. Food and Drug Administration announced its approval of a new formulation for Lantheus Holdings' prostate cancer imaging agent, Pylarify. This regulatory green light is anticipated to enhance patient access to crucial diagnostic scans by boosting production capabilities.
The revised formulation of Pylarify is specifically designed to streamline the manufacturing process. Lantheus expects this optimization to result in approximately a 50% increase in batch size. This expansion of production capacity is a key step in meeting the demand for this diagnostic tool.
Pylarify targets prostate-specific membrane antigen (PSMA), a protein frequently elevated in prostate cancer cells. It plays a vital role in detecting metastatic or recurrent disease in patients. The improved manufacturing is also projected to enhance the company's profit margins.
